TMS Co

TMS Co Financing Cash Flow

The Net Financing Cash Flow of TMS Co (4891.T) as of Nov 3, 2026 is 640.52 M JPY. In the previous year, Net Financing Cash Flow was 919,000.00 JPY — a change of 69,597.06% (higher).

Financing Cash Flow

640.52 MJPY

YoY

69,597.06%

Last updated:

Net Financing Cash Flow of TMS Co is 2026 640.52 M JPY. Net Financing Cash Flow of TMS Co was 2025 919,000.00 JPY. It decreases by 69,597.06% higher compared to the previous year.

The TMS Co Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2021
1.10 B JPY
Jan 1, 2022
246.48 M JPY
Jan 1, 2023
1.69 B JPY
Jan 1, 2024
688.13 M JPY
Jan 1, 2025
919,000.00 JPY
Jan 1, 2026
640.52 M JPY
The TMS Co Financing Cash Flow history
YEARFinancing Cash FlowYoY
640.52 MJPY+69,597.06%
919,000.00JPY-99.87%
688.13 MJPY-59.25%
1.69 BJPY+585.17%
246.48 MJPY-77.62%
1.10 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TMS Co Stock analysis

What does TMS Co do? TMS Co., Ltd. generates revenue through the research and development of pharmaceutical products and medical devices, focusing on drug candidates targeting soluble epoxide hydrolase (sEH). The company develops sEH inhibitors for inflammatory diseases, with its lead candidate TMS-007 undergoing clinical development for acute cerebral infarction. TMS-007 combines anti-inflammatory and thrombolytic effects by inhibiting sEH and acting on plasminogen. The follow-on product TMS-008 is in pre-clinical studies for various inflammatory diseases. The company collaborates with academia and research institutions for R&D results, leveraging external research to advance its pipeline. TMS Co., Ltd. targets the pharmaceutical market for inflammatory disease treatments, focusing on drug candidates with dual mechanisms of action. Its primary customers are pharmaceutical companies and research institutions seeking innovative therapeutic solutions. The company's pipeline includes TMS-007 for acute cerebral infarction and TMS-008 for broader inflammatory conditions, positioning itself in the biopharmaceutical segment. The firm's revenue model relies on advancing its pipeline through clinical and pre-clinical stages, with potential partnerships for further development and commercialization. TMS Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TMS Co stock

Net Financing Cash Flow of TMS Co is 640.52 M JPY in 2026.

Net Financing Cash Flow of TMS Co changed from 919,000.00 JPY to 640.52 M JPY, representing a 69,597.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow TMS Co since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's TMS Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — TMS Co

All Key Metrics — TMS Co